

# Luca Giovanella

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7290732/publications.pdf>

Version: 2024-02-01

409  
papers

9,613  
citations

46918

47  
h-index

91712

69  
g-index

422  
all docs

422  
docs citations

422  
times ranked

6975  
citing authors

#	ARTICLE	IF	CITATIONS
1	Controversies, Consensus, and Collaboration in the Use of <sup>131</sup> I Therapy in Differentiated Thyroid Cancer: A Joint Statement from the American Thyroid Association, the European Association of Nuclear Medicine, the Society of Nuclear Medicine and Molecular Imaging, and the European Thyroid Association. <i>Thyroid</i> , 2019, 29, 461-470.	2.4	257
2	Implications of Thyroglobulin Antibody Positivity in Patients with Differentiated Thyroid Cancer: A Clinical Position Statement. <i>Thyroid</i> , 2013, 23, 1211-1225.	2.4	152
3	[ <sup>18</sup> F]Fluorodeoxyglucose Positron Emission Tomography Predicts Survival After Chemoimmunotherapy for Primary Mediastinal Large B-Cell Lymphoma: Results of the International Extranodal Lymphoma Study Group IELSG-26 Study. <i>Journal of Clinical Oncology</i> , 2014, 32, 1769-1775.	0.8	149
4	Diagnostic performance of choline PET for detection of hyperfunctioning parathyroid glands in hyperparathyroidism: a systematic review and meta-analysis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 751-765.	3.3	149
5	Detection rate of <sup>99m</sup> Tc-FNA cytology in medullary thyroid carcinoma: a meta-analysis. <i>Clinical Endocrinology</i> , 2015, 82, 280-285.	1.2	145
6	Utility of baseline <sup>18</sup> F-FDG-PET/CT functional parameters in defining prognosis of primary mediastinal (thymic) large B-cell lymphoma. <i>Blood</i> , 2015, 126, 950-956.	0.6	138
7	Efficacy and safety of very low calorie ketogenic diet (VLCKD) in patients with overweight and obesity: A systematic review and meta-analysis. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2020, 21, 5-16.	2.6	136
8	The EANM practice guidelines for parathyroid imaging. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 2801-2822.	3.3	116
9	Efficacy of thermal ablation in benign non-functioning solid thyroid nodule: A systematic review and meta-analysis. <i>Endocrine</i> , 2020, 67, 35-43.	1.1	108
10	Performance of Five Ultrasound Risk Stratification Systems in Selecting Thyroid Nodules for FNA. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 1659-1669.	1.8	105
11	EANM practice guideline/SNMMI procedure standard for RAIU and thyroid scintigraphy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 2514-2525.	3.3	99
12	DIAGNOSIS OF ENDOCRINE DISEASE: Thyroglobulin measurement using highly sensitive assays in patients with differentiated thyroid cancer: a clinical position paper. <i>European Journal of Endocrinology</i> , 2014, 171, R33-R46.	1.9	94
13	Unstimulated Highly Sensitive Thyroglobulin in Follow-up of Differentiated Thyroid Cancer Patients: A Meta-Analysis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, 440-447.	1.8	92
14	Why the European Association of Nuclear Medicine has declined to endorse the 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 1001-1005.	3.3	92
15	Detection rate of <sup>99m</sup> Tc-MIBI single photon emission computed tomography (SPECT)/CT in preoperative planning for patients with primary hyperparathyroidism: A meta-analysis. <i>Head and Neck</i> , 2016, 38, E2159-72.	0.9	92
16	Long-Term Efficacy of a Single Session of RFA for Benign Thyroid Nodules: A Longitudinal 5-Year Observational Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 3751-3756.	1.8	92
17	Thyroglobulin levels and thyroglobulin doubling time independently predict a positive <sup>18</sup> F-FDG PET/CT scan in patients with biochemical recurrence of differentiated thyroid carcinoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2013, 40, 874-880.	3.3	90
18	Relationship between prostate-specific antigen kinetics and detection rate of radiolabelled choline PET/CT in restaging prostate cancer patients: a meta-analysis. <i>Clinical Chemistry and Laboratory Medicine</i> , 2014, 52, 725-33.	1.4	90

#	ARTICLE	IF	CITATIONS
19	Calcitonin measurement in aspiration needle washout fluids has higher sensitivity than cytology in detecting medullary thyroid cancer: a retrospective multicentre study. <i>Clinical Endocrinology</i> , 2014, 80, 135-140.	1.2	80
20	Detection Rate of 18F-Labeled PSMA PET/CT in Biochemical Recurrent Prostate Cancer: A Systematic Review and a Meta-Analysis. <i>Cancers</i> , 2019, 11, 710.	1.7	80
21	EANM practice guideline for PET/CT imaging in medullary thyroid carcinoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 61-77.	3.3	78
22	Hashimoto's encephalopathy: A rare proteiform disorder. <i>Autoimmunity Reviews</i> , 2016, 15, 466-476.	2.5	74
23	Diagnostic Performance and Prognostic Value of PET/CT with Different Tracers for Brain Tumors: A Systematic Review of Published Meta-Analyses. <i>International Journal of Molecular Sciences</i> , 2019, 20, 4669.	1.8	74
24	Medullary thyroid cancer diagnosis: An appraisal. <i>Head and Neck</i> , 2014, 36, 1216-1223.	0.9	73
25	The Role of 18F-FDG-PET and PET/CT in Patients with Sarcoidosis. <i>Academic Radiology</i> , 2014, 21, 675-684.	1.3	72
26	Diagnostic performance of 99mTc-MIBI scan in predicting the malignancy of thyroid nodules: a meta-analysis. <i>Endocrine</i> , 2013, 44, 70-78.	1.1	67
27	Additional value of integrated 18F-choline PET/4D contrast-enhanced CT in the localization of hyperfunctioning parathyroid glands and correlation with molecular profile. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 766-775.	3.3	67
28	Diagnostic performance of Fluorine-18-Fluorodeoxyglucose positron emission tomography for the diagnosis of osteomyelitis related to diabetic foot: A systematic review and a meta-analysis. <i>Foot</i> , 2013, 23, 140-148.	0.4	65
29	Serum calcitonin negative medullary thyroid carcinoma: a systematic review of the literature. <i>Clinical Chemistry and Laboratory Medicine</i> , 2015, 53, 1507-14.	1.4	64
30	Diagnostic Performance of Fluorine-18-Fluorodeoxyglucose Positron Emission Tomography in Patients with Merkel Cell Carcinoma: A Systematic Review and Meta-Analysis. <i>American Journal of Clinical Dermatology</i> , 2013, 14, 437-447.	3.3	63
31	Metabolic heterogeneity on baseline 18FDG-PET/CT scan is a predictor of outcome in primary mediastinal B-cell lymphoma. <i>Blood</i> , 2018, 132, 179-186.	0.6	63
32	Thyroglobulin measurement before rTSH <sup>131</sup> I ablation in detecting metastases from differentiated thyroid carcinoma. <i>Clinical Endocrinology</i> , 2008, 69, 659-663.	1.2	58
33	Thyroglobulin measurement by highly sensitive assays: focus on laboratory challenges. <i>Clinical Chemistry and Laboratory Medicine</i> , 2015, 53, 1301-14.	1.4	57
34	Prevalence of normal TSH value among patients with autonomously functioning thyroid nodule. <i>European Journal of Clinical Investigation</i> , 2015, 45, 739-744.	1.7	57
35	The Role of Fluorine-18-Fluorodeoxyglucose Positron Emission Tomography in Aggressive Histological Subtypes of Thyroid Cancer: An Overview. <i>International Journal of Endocrinology</i> , 2013, 2013, 1-6.	0.6	56
36	Clinical characteristics as predictors of malignancy in patients with indeterminate thyroid cytology: a meta-analysis. <i>Endocrine</i> , 2014, 46, 52-59.	1.1	56

#	ARTICLE	IF	CITATIONS
37	Molecular imaging with 99mTc-MIBI and molecular testing for mutations in differentiating benign from malignant follicular neoplasm: a prospective comparison. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 1018-1026.	3.3	55
38	Can ultrasound systems for risk stratification of thyroid nodules identify follicular carcinoma?. <i>Cancer Cytopathology</i> , 2020, 128, 250-259.	1.4	55
39	SARS-COV-2-related immune-inflammatory thyroid disorders: facts and perspectives. <i>Expert Review of Clinical Immunology</i> , 2021, 17, 737-759.	1.3	55
40	A Joint Statement from the American Thyroid Association, the European Association of Nuclear Medicine, the European Thyroid Association, the Society of Nuclear Medicine and Molecular Imaging on Current Diagnostic and Theranostic Approaches in the Management of Thyroid Cancer. <i>Thyroid</i> , 2021, 31, 1009-1019.	2.4	54
41	Heterophile antibodies may falsely increase or decrease thyroglobulin measurement in patients with differentiated thyroid carcinoma. <i>Clinical Chemistry and Laboratory Medicine</i> , 2009, 47, 952-4.	1.4	53
42	Use of fine-needle aspirate calcitonin to detect medullary thyroid carcinoma: A systematic review. <i>Diagnostic Cytopathology</i> , 2016, 44, 45-51.	0.5	53
43	Thyroid nodules with indeterminate cytology: prospective comparison between 18F-FDG-PET/CT, multiparametric neck ultrasonography, 99mTc-MIBI scintigraphy and histology. <i>European Journal of Endocrinology</i> , 2016, 174, 693-703.	1.9	53
44	The ultrasound risk stratification systems for thyroid nodule have been evaluated against papillary carcinoma. A meta-analysis. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2021, 22, 453-460.	2.6	53
45	Diagnostic Accuracy of 18F-FDG-PET and PET/CT in the Differential Diagnosis between Malignant and Benign Pleural Lesions. <i>Academic Radiology</i> , 2014, 21, 11-20.	1.3	52
46	Differentiated thyroid cancer patients potentially benefitting from postoperative I-131 therapy: a review of the literature of the past decade. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 78-83.	3.3	52
47	BRAF-mutated carcinomas among thyroid nodules with prior indeterminate FNA report: a systematic review and meta-analysis. <i>Clinical Endocrinology</i> , 2016, 84, 315-320.	1.2	51
48	Endocrine and metabolic adverse effects of immune checkpoint inhibitors: an overview (what) <i>Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 302</i>	1.8	51
49	Undetectable Thyroglobulin in Patients With Differentiated Thyroid Carcinoma and Residual Radioiodine Uptake on a Postablation Whole-Body Scan. <i>Clinical Nuclear Medicine</i> , 2011, 36, 109-112.	0.7	50
50	Procalcitonin for detecting medullary thyroid carcinoma: a systematic review. <i>Endocrine-Related Cancer</i> , 2015, 22, R157-R164.	1.6	50
51	Focal thyroid incidental uptake detected by 18F-fluorodeoxyglucose positron emission tomography. <i>Nuklearmedizin - NuclearMedicine</i> , 2013, 52, 130-136.	0.3	49
52	Highly sensitive thyroglobulin measurements in differentiated thyroid carcinoma management. <i>Clinical Chemistry and Laboratory Medicine</i> , 2008, 46, 1067-73.	1.4	48
53	Prevalence and malignancy risk of focal colorectal incidental uptake detected by <sup>18</sup> F-FDG-PET or PET/CT: a meta-analysis. <i>Radiology and Oncology</i> , 2014, 48, 99-104.	0.6	48
54	Levothyroxine Therapy: Changes of TSH Levels by Switching Patients from Tablet to Liquid Formulation. A Systematic Review and Meta-Analysis. <i>Frontiers in Endocrinology</i> , 2018, 9, 10.	1.5	48

#	ARTICLE	IF	CITATIONS
55	Performance of contrast-enhanced ultrasound (CEUS) in assessing thyroid nodules: a systematic review and meta-analysis using histological standard of reference. <i>Radiologia Medica</i> , 2020, 125, 406-415.	4.7	48
56	The role of positron emission tomography and positron emission tomography/computed tomography in thyroid tumours: an overview. <i>European Archives of Oto-Rhino-Laryngology</i> , 2013, 270, 1783-1787.	0.8	47
57	SAKK38/07 study: integration of baseline metabolic heterogeneity and metabolic tumor volume in DLBCL prognostic model. <i>Blood Advances</i> , 2020, 4, 1082-1092.	2.5	47
58	Imaging in primary hyperparathyroidism: focus on the evidence-based diagnostic performance of different methods. <i>Minerva Endocrinology</i> , 2018, 43, 133-143.	0.6	47
59	Heterophile Antibodies Rarely Influence the Measurement of Thyroglobulin and Thyroglobulin Antibodies in Differentiated Thyroid Cancer Patients. <i>Hormone and Metabolic Research</i> , 2010, 42, 736-739.	0.7	46
60	Relationship between serum thyroglobulin and <sup>18</sup> F-FDG PET/CT in <sup>131</sup> I-negative differentiated thyroid carcinomas. <i>Head and Neck</i> , 2012, 34, 626-631.	0.9	46
61	Will 18F-fluorocholine PET/CT replace other methods of preoperative parathyroid imaging?. <i>Endocrine</i> , 2021, 71, 285-297.	1.1	46
62	Evaluation of the first fully automated immunoassay method for the measurement of stimulating TSH receptor autoantibodies in Graves' disease. <i>Clinical Chemistry and Laboratory Medicine</i> , 2017, 55, 58-64.	1.4	45
63	Ultrasound features of medullary thyroid carcinoma correlate with cancer aggressiveness: a retrospective multicenter study. <i>Journal of Experimental and Clinical Cancer Research</i> , 2014, 33, 87.	3.5	44
64	Role of isotope scan, including positron emission tomography/computed tomography, in nodular goitre. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2014, 28, 507-518.	2.2	44
65	Cytological Diagnoses Associated with Noninvasive Follicular Thyroid Neoplasms with Papillary-Like Nuclear Features According to the Bethesda System for Reporting Thyroid Cytopathology: A Systematic Review and Meta-Analysis. <i>Thyroid</i> , 2019, 29, 222-228.	2.4	44
66	Alemtuzumab-induced thyroid events in multiple sclerosis: a systematic review and meta-analysis. <i>Journal of Endocrinological Investigation</i> , 2020, 43, 219-229.	1.8	44
67	Prevalence of thyroid dysfunction in patients with COVID-19: a systematic review. <i>Clinical and Translational Imaging</i> , 2021, 9, 233-240.	1.1	44
68	"False-positive" myocardial perfusion scintigraphy findings in patients with angiographically normal coronary arteries: insights from intravascular sonography studies. <i>Journal of Nuclear Medicine</i> , 2000, 41, 1935-40.	2.8	44
69	Thyroglobulin assay 4 weeks after thyroidectomy predicts outcome in low-risk papillary thyroid carcinoma. <i>Clinical Chemistry and Laboratory Medicine</i> , 2005, 43, 843-7.	1.4	43
70	Diagnostic value of thyroglobulin assay in cervical lymph node fine-needle aspirations for metastatic differentiated thyroid cancer. <i>Current Opinion in Oncology</i> , 2013, 25, 6-13.	1.1	43
71	Personalized management of differentiated thyroid cancer in real life – practical guidance from a multidisciplinary panel of experts. <i>Endocrine</i> , 2020, 70, 280-291.	1.1	43
72	Patient Age Is an Independent Risk Factor of Relapse of Differentiated Thyroid Carcinoma and Improves the Performance of the American Thyroid Association Stratification System. <i>Thyroid</i> , 2020, 30, 713-719.	2.4	43

#	ARTICLE	IF	CITATIONS
73	PET Imaging in Recurrent Medullary Thyroid Carcinoma. <i>International Journal of Molecular Imaging</i> , 2012, 2012, 1-9.	1.3	42
74	A multicentre validation study for the EUâ€TIRADS using histological diagnosis as a gold standard. <i>Clinical Endocrinology</i> , 2019, 91, 340-347.	1.2	42
75	Correlation between PSA kinetics and PSMAâ€PET in prostate cancer restaging: A metaâ€analysis. <i>European Journal of Clinical Investigation</i> , 2019, 49, e13063.	1.7	42
76	<sup>99m</sup> Tcâ€sestamibi scanning in thyroid nodules with nondiagnostic cytology. <i>Head and Neck</i> , 2010, 32, 607-611.	0.9	41
77	Prevalence and clinical significance of incidental F18-FDG breast uptake: a systematic review and meta-analysis. <i>Japanese Journal of Radiology</i> , 2014, 32, 59-68.	1.0	41
78	<sup>99m</sup> Tc-Methoxy-Isobutyl-Isonitrile Scintigraphy Is a Useful Tool for Assessing the Risk of Malignancy in Thyroid Nodules with Indeterminate Fine-Needle Cytology. <i>Thyroid</i> , 2016, 26, 1101-1109.	2.4	41
79	Accuracy of international ultrasound risk stratification systems in thyroid lesions cytologically classified as indeterminate. <i>Diagnostic Cytopathology</i> , 2017, 45, 113-117.	0.5	41
80	Undetectable Serum Thyroglobulin Due to Negative Interference of Heterophile Antibodies in Relapsing Thyroid Carcinoma. <i>Clinical Chemistry</i> , 2007, 53, 1871-1872.	1.5	40
81	Incidental uptake of 18F-fluorodeoxyglucose in the prostate gland. <i>Nuklearmedizin - NuclearMedicine</i> , 2014, 53, 249-258.	0.3	39
82	The role of fluorine-18-fluorodeoxyglucose positron emission tomography in evaluating the response to tyrosine-kinase inhibitors in patients with metastatic primary renal cell carcinoma. <i>Radiology and Oncology</i> , 2014, 48, 219-227.	0.6	39
83	Measurement of thyroglobulin, calcitonin, and PTH in FNA washout fluids. <i>Clinical Chemistry and Laboratory Medicine</i> , 2017, 55, 914-925.	1.4	39
84	Recent Developments of 18F-FET PET in Neuro-oncology. <i>Current Medicinal Chemistry</i> , 2018, 25, 3061-3073.	1.2	39
85	Undetectable or low (<1 ng/ml) postsurgical thyroglobulin values do not rule out metastases in early stage differentiated thyroid cancer patients. <i>Oncotarget</i> , 2018, 9, 17491-17500.	0.8	39
86	Semi-quantitative assessment of 99Tcm-sestamibi uptake in lung cancer. <i>Nuclear Medicine Communications</i> , 1997, 18, 1087-1097.	0.5	38
87	Chromogranin-A as a Serum Marker for Neuroendocrine Tumors: Comparison with Neuron-Specific Enolase and Correlation with Immunohistochemical Findings. <i>International Journal of Biological Markers</i> , 1999, 14, 160-166.	0.7	38
88	Thyroglobulin assay during thyroxine treatment in low-risk differentiated thyroid cancer management: comparison with recombinant human thyrotropin-stimulated assay and imaging procedures. <i>Clinical Chemistry and Laboratory Medicine</i> , 2006, 44, 648-52.	1.4	38
89	Reliability of real-time elastography to diagnose thyroid nodules previously read at FNAC as indeterminate: a meta-analysis. <i>Endocrine</i> , 2015, 50, 335-343.	1.1	38
90	Diagnostic Role of 18F-PSMA-1007 PET/CT in Prostate Cancer Staging: A Systematic Review. <i>Diagnostics</i> , 2021, 11, 552.	1.3	38

#	ARTICLE	IF	CITATIONS
91	ENDOCRINOLOGY IN THE TIME OF COVID-19: Management of thyroid nodules and cancer. European Journal of Endocrinology, 2020, 183, G41-G48.	1.9	38
92	Natriuretic peptides as markers of preclinical cardiac disease in obesity. European Journal of Clinical Investigation, 2004, 34, 342-348.	1.7	37
93	Immunohistochemistry for BRAF(V600E) Antibody VE1 Performed in Core Needle Biopsy Samples Identifies Mutated Papillary Thyroid Cancers. Hormone and Metabolic Research, 2014, 46, 370-374.	0.7	37
94	Comparison of serum calcitonin and procalcitonin in detecting medullary thyroid carcinoma among patients with thyroid nodules. Clinical Chemistry and Laboratory Medicine, 2013, 51, 1477-81.	1.4	36
95	Preoperative Measurement of Serum Thyroglobulin to Predict Malignancy in Thyroid Nodules: A Systematic Review. Hormone and Metabolic Research, 2015, 47, 247-252.	0.7	36
96	Italian consensus for the classification and reporting of thyroid cytology: the risk of malignancy between indeterminate lesions at low or high risk. A systematic review and meta-analysis. Endocrine, 2019, 63, 430-438.	1.1	36
97	Diagnostic testing for Graves' or non-Graves' hyperthyroidism: A comparison of two thyrotropin receptor antibody immunoassays with thyroid scintigraphy and ultrasonography. Clinical Endocrinology, 2020, 92, 169-178.	1.2	36
98	Postsurgery serum thyroglobulin disappearance kinetic in patients with differentiated thyroid carcinoma. Head and Neck, 2010, 32, 568-571.	0.9	35
99	Thyroglobulin measurement on fine-needle washout fluids: Influence of sample collection methods. Diagnostic Cytopathology, 2009, 37, 42-44.	0.5	35
100	Is Malignant Nodule Topography an Additional Risk Factor for Metastatic Disease in Low-Risk Differentiated Thyroid Cancer?. Thyroid, 2014, 24, 1607-1611.	2.4	35
101	PET imaging in ectopic Cushing syndrome: a systematic review. Endocrine, 2015, 50, 297-305.	1.1	34
102	High-intensity focused ultrasound (HIFU) for benign thyroid nodules: 2-year follow-up results. Endocrine, 2019, 65, 312-317.	1.1	34
103	Impact of 18F-FDG PET/CT in Staging Patients With Small Cell Lung Cancer: A Systematic Review and Meta-Analysis. Frontiers in Medicine, 2019, 6, 336.	1.2	34
104	Low or Undetectable Basal Thyroglobulin Levels Obviate the Need for Neck Ultrasound in Differentiated Thyroid Cancer Patients After Total Thyroidectomy and <sup>131</sup> I Ablation. Thyroid, 2018, 28, 722-728.	2.4	33
105	PET/CT in thyroid nodule and differentiated thyroid cancer patients. The evidence-based state of the art. Reviews in Endocrine and Metabolic Disorders, 2019, 20, 47-64.	2.6	33
106	Diagnosis, Treatment Response, and Prognosis: The Role of <sup>18</sup> F-DOPA PET/CT in Children Affected by Neuroblastoma in Comparison with <sup>123</sup> I-mIBG Scan: The First Prospective Study. Journal of Nuclear Medicine, 2020, 61, 367-374.	2.8	33
107	Columnar cell variant of papillary thyroid carcinoma: Cytomorphological characteristics of 11 cases with histological correlation and literature review. Cancer Cytopathology, 2017, 125, 389-397.	1.4	32
108	High-intensity focused ultrasound (HIFU) therapy for benign thyroid nodules without anesthesia or sedation. Endocrine, 2018, 61, 210-215.	1.1	32

#	ARTICLE	IF	CITATIONS
109	Performance of EU-TIRADS in malignancy risk stratification of thyroid nodules: a meta-analysis. <i>European Journal of Endocrinology</i> , 2020, 183, 255-264.	1.9	32
110	Unstimulated high sensitive thyroglobulin measurement predicts outcome of differentiated thyroid carcinoma. <i>Clinical Chemistry and Laboratory Medicine</i> , 2009, 47, 1001-4.	1.4	31
111	<sup>18</sup> F-FDG uptake as a prognostic variable in primary differentiated thyroid cancer incidentally detected by PET/CT: a multicentre study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 1482-1491.	3.3	31
112	Positron Emission Tomography/Computed Tomography Assessment After Immunochemotherapy and Irradiation Using the Lugano Classification Criteria in the IELSG-26 Study of Primary Mediastinal B-Cell Lymphoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 97, 42-49.	0.4	31
113	Galactin-3 Performance in Histologic and Cytologic Assessment of Thyroid Nodules: A Systematic Review and Meta-Analysis. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1756.	1.8	31
114	<sup>68</sup> Ga-PSMA PET thyroid incidentalomas. <i>Hormones</i> , 2019, 18, 145-149.	0.9	31
115	Diagnostic performance of PET/CT with tracers other than F-18-FDG in oncology: an evidence-based review. <i>Clinical and Translational Oncology</i> , 2014, 16, 770-775.	1.2	30
116	Prevalence and risk of malignancy of focal incidental uptake detected by fluorine-18-fluorodeoxyglucose positron emission tomography in the parotid gland: a meta-analysis. <i>European Archives of Oto-Rhino-Laryngology</i> , 2015, 272, 3617-3626.	0.8	30
117	Searching for the most effective thyrotropin (TSH) threshold to rule-out autonomously functioning thyroid nodules in iodine deficient regions. <i>Endocrine</i> , 2016, 54, 757-761.	1.1	30
118	Procalcitonin measurement to screen medullary thyroid carcinoma: A prospective evaluation in a series of 2705 patients with thyroid nodules. <i>European Journal of Clinical Investigation</i> , 2018, 48, e12934.	1.7	30
119	Lymph Node Thyroglobulin Measurement in Diagnosis of Neck Metastases of Differentiated Thyroid Carcinoma. <i>Journal of Thyroid Research</i> , 2011, 2011, 1-7.	0.5	29
120	Thyroid nodules with indeterminate cytology: molecular imaging with <sup>99m</sup> Tc-methoxyisobutylisonitrile (MIBI) is more cost-effective than the Afirma® gene expression classifier. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 1497-1500.	3.3	29
121	Differentiating malignant from benign thyroid nodules with indeterminate cytology by <sup>99m</sup> Tc-MIBI scan: a new quantitative method for improving diagnostic accuracy. <i>Scientific Reports</i> , 2017, 7, 6147.	1.6	29
122	Impact of non-invasive follicular thyroid neoplasms with papillary-like nuclear features (NIFTP) on risk of malignancy in patients undergoing lobectomy/thyroidectomy for suspected malignancy or malignant fine-needle aspiration cytology findings: a systematic review and meta-analysis. <i>European Journal of Endocrinology</i> , 2019, 181, 389-396.	1.9	29
123	High-Sensitivity Human Thyroglobulin (hTG) Immunoradiometric Assay in the Follow-up of Patients with Differentiated Thyroid Cancer. <i>Clinical Chemistry and Laboratory Medicine</i> , 2002, 40, 480-4.	1.4	28
124	Ectopic Substernal Thyroid Tissue: A Challenging Differential Diagnosis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, 719-720.	1.8	28
125	American Thyroid Association ultrasound system for the initial assessment of thyroid nodules: Use in stratifying the risk of malignancy of indeterminate lesions. <i>Head and Neck</i> , 2018, 40, 722-727.	0.9	27
126	<sup>18</sup> FDG-positron emission tomography/computed tomography (PET/CT) scanning in thyroid nodules with nondiagnostic cytology. <i>Clinical Endocrinology</i> , 2011, 74, 644-648.	1.2	26



#	ARTICLE	IF	CITATIONS
127	Prevalence of gastrointestinal disorders having an impact on tablet levothyroxine absorption: should this formulation still be considered as the first-line therapy?. <i>Endocrine</i> , 2020, 67, 281-290.	1.1	26
128	Prevalence and Significance of Hypermetabolic Lymph Nodes Detected by 2-[18F]FDG PET/CT after COVID-19 Vaccination: A Systematic Review and a Meta-Analysis. <i>Pharmaceuticals</i> , 2021, 14, 762.	1.7	26
129	Radiolabelled choline versus PSMA PET/CT in prostate cancer restaging: a meta-analysis. <i>American Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 9, 127-139.	1.0	26
130	Chromogranin A immunoradiometric assay in diagnosis of pheochromocytoma: comparison with plasma metanephrines and 123I-MIBG scan. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2006, 50, 344-7.	0.4	25
131	Spurious hypercalcitoninemia and heterophilic antibodies in patients with thyroid nodules. <i>Head and Neck</i> , 2011, 33, 95-97.	0.9	24
132	18F-FDG Uptake Changes in Liver and Mediastinum During Chemotherapy in Patients With Diffuse Large B-cell Lymphoma. <i>Clinical Nuclear Medicine</i> , 2012, 37, 949-952.	0.7	24
133	Treatment of benign thyroid nodules by high intensity focused ultrasound (HIFU) at different acoustic powers: a study on in-silico phantom. <i>Endocrine</i> , 2018, 59, 506-509.	1.1	24
134	Efficacy of Vandetanib in Treating Locally Advanced or Metastatic Medullary Thyroid Carcinoma According to RECIST Criteria: A Systematic Review and Meta-Analysis. <i>Frontiers in Endocrinology</i> , 2018, 9, 224.	1.5	24
135	Comparison of high intensity focused ultrasound and radioiodine for treating toxic thyroid nodules. <i>Clinical Endocrinology</i> , 2018, 89, 219-225.	1.2	24
136	Low free-T3 serum levels and prognosis of COVID-19: systematic review and meta-analysis. <i>Clinical Chemistry and Laboratory Medicine</i> , 2021, 59, 1906-1913.	1.4	24
137	Preoperative undetectable serum thyroglobulin in differentiated thyroid carcinoma: incidence, causes and management strategy. <i>Clinical Endocrinology</i> , 2007, 67, 070611021303003-???	1.2	23
138	Postsurgical thyroid remnant estimation by <sup>99m</sup> Tc <sup>99m</sup> perchnetate scintigraphy predicts radioiodine ablation effectiveness in patients with differentiated thyroid carcinoma. <i>Head and Neck</i> , 2011, 33, 552-556.	0.9	23
139	The 2015 Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma: the "evidence-based" refusal to endorse them by EANM due to the "not evidence-based" marginalization of the role of Nuclear Medicine. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 1486-1490.	3.3	23
140	Radiomics Analysis of [ <sup>18</sup> F]-Fluorodeoxyglucose-Avid Thyroid Incidentalomas Improves Risk Stratification and Selection for Clinical Assessment. <i>Thyroid</i> , 2021, 31, 88-95.	2.4	23
141	Determining an energy threshold for optimal volume reduction of benign thyroid nodules treated by radiofrequency ablation. <i>European Radiology</i> , 2021, 31, 5189-5197.	2.3	23
142	Assessment of myocardial area at risk by technetium-99m sestamibi during coronary artery occlusion: comparison between three tomographic methods of quantification. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1996, 23, 31-39.	2.2	22
143	Serum Procalcitonin and Calcitonin Normal Values Before and After Calcium Gluconate Infusion. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2012, 120, 169-170.	0.6	22
144	Ultrasound systems for risk stratification of thyroid nodules prompt inappropriate biopsy in autonomously functioning thyroid nodules. <i>Clinical Endocrinology</i> , 2020, 93, 67-75.	1.2	22

#	ARTICLE	IF	CITATIONS
145	Primary hyperparathyroidism with surgical indication and negative or equivocal scintigraphy: safety and reliability of PTH washout. A systematic review and meta-analysis. <i>European Journal of Endocrinology</i> , 2019, 181, 245-253.	1.9	22
146	Serum calcitonin-negative medullary thyroid carcinoma: role of CgA and CEA as complementary markers. <i>International Journal of Biological Markers</i> , 2008, 23, 129-131.	0.7	22
147	Thyroid volume influences serum calcitonin levels in a thyroid-healthy population: results of a 3-assay, 519 subjects study. <i>Clinical Chemistry and Laboratory Medicine</i> , 2012, 50, 895-900.	1.4	21
148	Thyroid lobe ablation with iodine-131 in patients with differentiated thyroid carcinoma. <i>Nuclear Medicine Communications</i> , 2013, 34, 767-770.	0.5	21
149	Laser capture microdissection is a valuable tool in the preoperative molecular screening of follicular lesions of the thyroid: an institutional experience. <i>Cytopathology</i> , 2015, 26, 288-296.	0.4	21
150	Thyroid remnant ablation in differentiated thyroid cancer. <i>Nuclear Medicine Communications</i> , 2015, 36, 1100-1106.	0.5	21
151	Radioiodine treatment after surgery for differentiated thyroid cancer: a reasonable option. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 918-925.	3.3	21
152	Detection rate of somatostatin receptor PET in patients with recurrent medullary thyroid carcinoma: a systematic review and a meta-analysis. <i>Hormones</i> , 2018, 16, 362-372.	0.9	21
153	Appropriate Use Criteria for Nuclear Medicine in the Evaluation and Treatment of Differentiated Thyroid Cancer. <i>Journal of Nuclear Medicine</i> , 2020, 61, 375-396.	2.8	21
154	Indeterminate thyroid nodules. The role of 18F-FDG PET/CT in the assessment of ultrasonography risk stratification systems and new thyroid cytology classifications. <i>Endocrine</i> , 2020, 69, 553-561.	1.1	21
155	Management of Differentiated Thyroid Cancer: The Standard of Care. <i>Journal of Nuclear Medicine</i> , 2022, 63, 189-195.	2.8	21
156	MANAGEMENT OF ENDOCRINE DISEASE: The role of rhTSH in the management of differentiated thyroid cancer: pros and cons. <i>European Journal of Endocrinology</i> , 2019, 181, R133-R145.	1.9	21
157	Evolving role of PET/CT with different tracers in the evaluation of pulmonary neuroendocrine tumours. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 853-855.	3.3	20
158	Prognostic models for primary mediastinal (thymic) B-cell lymphoma derived from 18F-FDG PET/CT quantitative parameters in the International Extranodal Lymphoma Study Group (IELSG) 26 study. <i>British Journal of Haematology</i> , 2017, 178, 588-591.	1.2	20
159	Radioactive Iodine Therapy for Differentiated Thyroid Cancer: Lessons from Confronting Controversial Literature on Risks for Secondary Malignancy. <i>Journal of Nuclear Medicine</i> , 2018, 59, 723-725.	2.8	20
160	Performance of the Italian Consensus for the Classification and Reporting of Thyroid Cytology (ICRTC) in discriminating indeterminate lesions at low and high risk of malignancy. A systematic review and meta-analysis. <i>Endocrine</i> , 2018, 60, 31-35.	1.1	20
161	Fine-needle aspiration to diagnose primary thyroid lymphomas: a systematic review and meta-analysis. <i>European Journal of Endocrinology</i> , 2019, 180, 177-187.	1.9	20
162	Molecular Imaging and Theragnostics of Thyroid Cancers. <i>Cancers</i> , 2022, 14, 1272.	1.7	20

#	ARTICLE	IF	CITATIONS
163	Interference in thyroid-stimulating hormone determination. <i>European Journal of Clinical Investigation</i> , 2010, 40, 756-758.	1.7	19
164	Serum thyroglobulin reference values according to NACB criteria in healthy subjects with normal thyroid ultrasound. <i>Clinical Chemistry and Laboratory Medicine</i> , 2012, 50, 891-3.	1.4	19
165	High-sensitive basal serum thyroglobulin 6-12 months after thyroid ablation is strongly associated with early response to therapy and event-free survival in patients with low-to-intermediate risk differentiated thyroid carcinomas. <i>European Journal of Endocrinology</i> , 2017, 176, 497-504.	1.9	19
166	Thyroglobulin autoantibodies before radioiodine ablation predict differentiated thyroid cancer outcome. <i>Clinical Chemistry and Laboratory Medicine</i> , 2017, 55, 1995-2001.	1.4	19
167	Procalcitonin as a postoperative marker in the follow-up of patients affected by medullary thyroid carcinoma. <i>International Journal of Biological Markers</i> , 2018, 33, 156-160.	0.7	19
168	Early post-treatment risk stratification of differentiated thyroid cancer: comparison of three high-sensitive Tg assays. <i>European Journal of Endocrinology</i> , 2018, 178, 75-82.	1.9	19
169	Medullary Thyroid Nodules by Measurement of Calcitonin (Ct) in Aspiration Needle Washout in Patients with Multinodular Goiter and Moderately Elevated Serum Ct. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2012, 120, 234-237.	0.6	18
170	Serum cytokeratin 19 fragments: a dedifferentiation marker in advanced thyroid cancer. <i>European Journal of Endocrinology</i> , 2012, 167, 793-797.	1.9	18
171	Differentiated thyroid cancer patients with a previous indeterminate (Thy 3) cytology have a better prognosis than those with suspicious or malignant FNAC reports. <i>Endocrine</i> , 2015, 49, 191-195.	1.1	18
172	DIAGNOSIS OF ENDOCRINE DISEASE: High-yield thyroid fine-needle aspiration cytology: an update focused on ancillary techniques improving its accuracy. <i>European Journal of Endocrinology</i> , 2016, 174, R53-R63.	1.9	18
173	Thyroxine Treatment With Softgel Capsule Formulation: Usefulness in Hypothyroid Patients Without Malabsorption. <i>Frontiers in Endocrinology</i> , 2018, 9, 118.	1.5	18
174	Performance of 18F-FDG PET/CT in Selecting Thyroid Nodules with Indeterminate Fine-Needle Aspiration Cytology for Surgery. A Systematic Review and a Meta-Analysis.. <i>Journal of Clinical Medicine</i> , 2019, 8, 1333.	1.0	18
175	Testing for BRAF (V600E) Mutation in Thyroid Nodules with Fine-Needle Aspiration (FNA) Read as Suspicious for Malignancy (Bethesda V, Thy4, TIR4): a Systematic Review and Meta-analysis. <i>Endocrine Pathology</i> , 2020, 31, 57-66.	5.2	18
176	Detecting N-RAS Q61R Mutated Thyroid Neoplasias by Immunohistochemistry. <i>Endocrine Pathology</i> , 2017, 28, 71-74.	5.2	17
177	Differentiated Thyroid Cancer lymph-node relapse. Role of adjuvant radioactive iodine therapy after lymphadenectomy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 926-934.	3.3	17
178	Detection rate of unknown primary tumour by using somatostatin receptor PET/CT in patients with metastatic neuroendocrine tumours: a meta-analysis. <i>Endocrine</i> , 2019, 64, 456-468.	1.1	17
179	Different Formulations of Levothyroxine for Treating Hypothyroidism: A Real-Life Study. <i>International Journal of Endocrinology</i> , 2020, 2020, 1-5.	0.6	17
180	Radiomics analysis improves 18FDG PET/CT-based risk stratification of cytologically indeterminate thyroid nodules. <i>Endocrine</i> , 2022, 75, 202-210.	1.1	17

#	ARTICLE	IF	CITATIONS
181	Thyroglobulin Autoantibodies as Surrogate Biomarkers in the Management of Patients with Differentiated Thyroid Carcinoma. <i>Current Medicinal Chemistry</i> , 2014, 21, 3687-3692.	1.2	17
182	Thyroid Metastases from Typical Carcinoid of the Lung Differentiating Between Medullary Thyroid Carcinoma and Neuroendocrine Tumor Metastasis to the Thyroid. <i>Thyroid</i> , 2009, 19, 521-526.	2.4	16
183	Comparison of thyroglobulin antibody interference in first- and second-generation thyroglobulin immunoassays. <i>Clinical Chemistry and Laboratory Medicine</i> , 2011, 49, 1025-1027.	1.4	16
184	High Sensitive Thyroglobulin Assay on Thyroxine Therapy: Can it Avoid Stimulation Test in Low and High Risk Differentiated Thyroid Carcinoma Patients?. <i>Hormone and Metabolic Research</i> , 2013, 45, 664-668.	0.7	16
185	Evaluation of the BRAHMS Kryptor <sup>®</sup> Thyroglobulin Minirecovery Test in patients with differentiated thyroid carcinoma. <i>Clinical Chemistry and Laboratory Medicine</i> , 2013, 51, 449-453.	1.4	16
186	The "reset button" revisited: why high activity 131I therapy of advanced differentiated thyroid cancer after dosimetry is advantageous for patients. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 915-917.	3.3	16
187	Diagnostic Performance of PET or PET/CT Using 18F-FDG Labeled White Blood Cells in Infectious Diseases: A Systematic Review and a Bivariate Meta-Analysis. <i>Diagnostics</i> , 2019, 9, 60.	1.3	16
188	Circulating biomarkers for the detection of tumor recurrence in the postsurgical follow-up of differentiated thyroid carcinoma. <i>Current Opinion in Oncology</i> , 2020, 32, 7-12.	1.1	16
189	Detection Rate of Culprit Tumors Causing Osteomalacia Using Somatostatin Receptor PET/CT: Systematic Review and Meta-Analysis. <i>Diagnostics</i> , 2020, 10, 2.	1.3	16
190	Higher thyroid hormone levels and cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 808-821.	3.3	16
191	Early preablation rhTSH-stimulated thyroglobulin predicts outcome of differentiated thyroid cancer (DTC) patients. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 2466-2475.	3.3	16
192	Second-generation Thyrotropin Receptor Antibodies Assay and Quantitative Thyroid Scintigraphy in Autoimmune Hyperthyroidism. <i>Hormone and Metabolic Research</i> , 2008, 40, 484-486.	0.7	15
193	Could Different Hydration Protocols Affect the Quality of 18F-FDG PET/CT Images?. <i>Journal of Nuclear Medicine Technology</i> , 2011, 39, 77-82.	0.4	15
194	Real-time elastography in autonomously functioning thyroid nodules: relationship with TSH levels, scintigraphy, and ultrasound patterns. <i>Endocrine</i> , 2017, 58, 488-494.	1.1	15
195	Role of serum cytokeratin 19 fragment (Cyfra 21.1) as a prognostic biomarker in patients with differentiated thyroid cancer. <i>Scientific Reports</i> , 2017, 7, 7359.	1.6	15
196	Fine-needle aspiration in all thyroid incidentalomas at <sup>18</sup> F-FDG PET/CT: Can EU-TIRADS revise the dogma?. <i>Clinical Endocrinology</i> , 2018, 89, 642-648.	1.2	15
197	Unstimulated high-sensitive thyroglobulin is a powerful prognostic predictor in patients with thyroid cancer. <i>Clinical Chemistry and Laboratory Medicine</i> , 2019, 58, 130-137.	1.4	15
198	Errare humanum est, sed in errare perseverare diabolicum: methodological errors in the assessment of the relationship between I-131 therapy and possible increases in the incidence of malignancies. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 519-522.	3.3	15

#	ARTICLE	IF	CITATIONS
199	False-positive serum chromogranin A assay due to heterophile antibody interference. <i>Clinica Chimica Acta</i> , 2007, 379, 171-172.	0.5	14
200	Three-Dimensional Ordered-Subset Expectation Maximization Iterative Protocol for Evaluation of Left Ventricular Volumes and Function by Quantitative Gated SPECT: A Dynamic Phantom Study. <i>Journal of Nuclear Medicine Technology</i> , 2010, 38, 18-23.	0.4	14
201	Calcitonin measurement on fine needle washouts: Preanalytical Issues and Normal Reference Values. <i>Diagnostic Cytopathology</i> , 2013, 41, 226-229.	0.5	14
202	HER2 Analysis in Sporadic Thyroid Cancer of Follicular Cell Origin. <i>International Journal of Molecular Sciences</i> , 2016, 17, 2040.	1.8	14
203	Reflex TSH strategy: the good, the bad and the ugly. <i>Clinical Chemistry and Laboratory Medicine</i> , 2019, 58, 1-2.	1.4	14
204	Radioisotope imaging for discriminating benign from malignant cytologically indeterminate thyroid nodules. <i>Gland Surgery</i> , 2019, 8, S118-S125.	0.5	14
205	Baseline PET features to predict prognosis in primary mediastinal B cell lymphoma: a comparative analysis of different methods for measuring baseline metabolic tumour volume. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 1334-1344.	3.3	14
206	Prognostic models integrating quantitative parameters from baseline and interim positron emission computed tomography in patients with diffuse large B cell lymphoma: post hoc analysis from the SAKK38/07 clinical trial. <i>Hematological Oncology</i> , 2020, 38, 715-725.	0.8	14
207	Circulating cytokeratin 19 fragments in patients with benign nodules and carcinomas of the thyroid gland. <i>International Journal of Biological Markers</i> , 2008, 23, 54-57.	0.7	14
208	Life after thyroid cancer: the role of thyroglobulin and thyroglobulin antibodies for postoperative follow-up. <i>Expert Review of Endocrinology and Metabolism</i> , 2021, 16, 273-279.	1.2	14
209	Langherans Cell Histiocytosis of the Thyroid Gland Detected by 18FDG-PET/CT. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007, 92, 2866-2867.	1.8	13
210	131I whole-body scan or 18FDG PET/CT for patients with elevated thyroglobulin and negative ultrasound?. <i>Clinical and Translational Imaging</i> , 2013, 1, 175-183.	1.1	13
211	Prevalence and Risk of Malignancy of Thyroid Incidentalomas Detected by <sup>18</sup> F-Fluorodeoxyglucose Positron-Emission Tomography. <i>Thyroid</i> , 2013, 23, 124-126.	2.4	13
212	Well-Differentiated Follicular Patterned Tumors of the Thyroid With High-Grade Features Can Metastasize in the Absence of Capsular or Vascular Invasion. <i>International Journal of Surgical Pathology</i> , 2014, 22, 749-756.	0.4	13
213	Prevalence and clinical significance of focal incidental 18F-FDG uptake in different organs: an evidence-based summary. <i>Clinical and Translational Imaging</i> , 2017, 5, 525-532.	1.1	13
214	Procalcitonin as Marker of Recurrent Medullary Thyroid Carcinoma: A Systematic Review and Meta-Analysis. <i>Endocrinology and Metabolism</i> , 2018, 33, 204.	1.3	13
215	Reliability of core needle biopsy as a second-line procedure in thyroid nodules with an indeterminate fine-needle aspiration report: a systematic review and meta-analysis. <i>Ultrasonography</i> , 2018, 37, 121-128.	1.0	13
216	Generation and validation of a PET radiomics model that predicts survival in diffuse large B cell lymphoma treated with R-CHOP14: A SAKK 38/07 trial post hoc analysis. <i>Hematological Oncology</i> , 2022, 40, 12-22.	0.8	13

#	ARTICLE	IF	CITATIONS
217	Circulating procalcitonin in aseptic carcinoma patients: a specificity study with <sup>18</sup> F-fluorodeoxyglucose positron-emission tomography/computed tomography as benchmark. <i>Clinical Chemistry and Laboratory Medicine</i> , 2010, 48, 1163-1165.	1.4	12
218	Thyrotropin Values in Patients with Micropapillary Thyroid Cancer Versus Benign Nodular Disease. <i>Endocrine Practice</i> , 2013, 19, 651-655.	1.1	12
219	Relationship Between Antithyroglobulin Autoantibodies and Thyroglobulin Recovery Rates Using Different Thyroglobulin Concentrations in the Recovery Buffer. <i>Hormone and Metabolic Research</i> , 2013, 45, 728-735.	0.7	12
220	Multicentre study of 18F-FDG-PET/CT prostate incidental uptake. <i>Japanese Journal of Radiology</i> , 2015, 33, 538-546.	1.0	12
221	Multicentre clinical evaluation of the new highly sensitive Elecsys <sup>®</sup> thyroglobulin assay in patients with differentiated thyroid carcinoma. <i>Clinical Endocrinology</i> , 2018, 88, 295-302.	1.2	12
222	Postoperative serum thyroglobulin and neck ultrasound to drive decisions about iodine-131 therapy in patients with differentiated thyroid carcinoma: an evidence-based strategy?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 2155-2158.	3.3	12
223	Risk of Malignancy (ROM) of Thyroid FNA Diagnosed as Suspicious for Malignancy or Malignant: an Institutional Experience with Systematic Review and Meta-Analysis of Literature. <i>Endocrine Pathology</i> , 2020, 31, 52-56.	5.2	12
224	FNA indication according to ACR-TIRADS, EU-TIRADS and K-TIRADS in thyroid incidentalomas at 18F-FDG PET/CT. <i>Journal of Endocrinological Investigation</i> , 2020, 43, 1607-1612.	1.8	12
225	Procalcitonin as an Alternative Tumor Marker of Medullary Thyroid Carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, 3634-3643.	1.8	12
226	Global FT4 immunoassay standardization: an expert opinion review. <i>Clinical Chemistry and Laboratory Medicine</i> , 2021, 59, 1013-1023.	1.4	12
227	Multi-field-of-view SPECT is superior to whole-body scanning for assessing metastatic bone disease in patients with prostate cancer. <i>Tumori</i> , 2011, 97, 629-33.	0.6	12
228	Graves' Disease, Thymus Enlargement, and Hypercalcemia. <i>New England Journal of Medicine</i> , 2008, 358, 1078-1079.	13.9	11
229	PET and PET/CT imaging in thyroid and adrenal diseases: an update. <i>Hormones</i> , 2013, 12, 327-333.	0.9	11
230	Measuring procalcitonin to overcome heterophilic-antibody-induced spurious hypercalcitoninemia. <i>Clinical Chemistry and Laboratory Medicine</i> , 2018, 56, e191-e193.	1.4	11
231	F18-choline/C11-choline PET/CT thyroid incidentalomas. <i>Endocrine</i> , 2019, 64, 203-208.	1.1	11
232	Detection of thyroiditis on PET/CT imaging: a systematic review. <i>Hormones</i> , 2020, 19, 341-349.	0.9	11
233	SARS-CoV-2-related thyroid disorders: a synopsis for nuclear medicine thyroidologists. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 1719-1723.	3.3	11
234	Molecular Imaging for Thyrotoxicosis and Thyroid Nodules. <i>Journal of Nuclear Medicine</i> , 2021, 62, 20S-25S.	2.8	11

#	ARTICLE	IF	CITATIONS
235	Isthmus topography is a risk factor for persistent disease in patients with differentiated thyroid cancer. <i>European Journal of Endocrinology</i> , 2021, 185, 397-404.	1.9	11
236	Updated clinical management guidance during the COVID-19 pandemic: thyroid nodules and cancer. <i>European Journal of Endocrinology</i> , 2022, 186, G1-G7.	1.9	11
237	Chromogranin-A as a serum marker for neuroendocrine tumors: comparison with neuron-specific enolase and correlation with immunohistochemical findings. <i>International Journal of Biological Markers</i> , 1999, 14, 160-6.	0.7	11
238	Evaluation of chromogranin A expression in serum and tissues of breast cancer patients. <i>International Journal of Biological Markers</i> , 2001, 16, 268-72.	0.7	11
239	False-negative thyroglobulin measurement in recurrent/metastatic thyroid carcinomas. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2009, 36, 326-327.	3.3	10
240	Hyperfunctioning Solid/Trabecular Follicular Carcinoma of the Thyroid Gland. <i>Journal of Oncology</i> , 2010, 2010, 1-4.	0.6	10
241	Positron emission tomography/computed tomography in patients treated for differentiated thyroid carcinomas. <i>Expert Review of Endocrinology and Metabolism</i> , 2012, 7, 35-43.	1.2	10
242	CDX2 Expression in Columnar Variant of Papillary Thyroid Carcinoma. <i>Thyroid</i> , 2013, 23, 1498-1499.	2.4	10
243	The essential use of FNA-calcitonin for detecting medullary thyroid cancer. <i>Endocrine</i> , 2014, 47, 342-344.	1.1	10
244	Radioiodine Ablation of Remaining Thyroid Lobe in Patients with Differentiated Thyroid Cancer Treated by Lobectomy: A Systematic Review and Metaanalysis. <i>Journal of Nuclear Medicine</i> , 2020, 61, 1730-1735.	2.8	10
245	How to better stratify the risk of differentiated thyroid carcinomas: the key role of radioactive iodine therapy, age, and gender. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 822-830.	3.3	10
246	Clinical performance of calcitonin and procalcitonin Elecsys <sup>®</sup> immunoassays in patients with medullary thyroid carcinoma. <i>Clinical Chemistry and Laboratory Medicine</i> , 2021, 59, 743-747.	1.4	10
247	Radioiodine therapy of advanced differentiated thyroid cancer: clinical considerations and multidisciplinary approach. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 63, 229-234.	0.4	10
248	Multidisciplinary approach for risk-oriented treatment of low-risk papillary thyroid cancer in Switzerland. <i>Swiss Medical Weekly</i> , 2019, 149, w14700.	0.8	10
249	Is thyroglobulin a reliable biomarker of differentiated thyroid cancer in patients treated by lobectomy? A systematic review and meta-analysis. <i>Clinical Chemistry and Laboratory Medicine</i> , 2022, 60, 1091-1100.	1.4	10
250	F-18 FDG PET-CT Imaging in the Care-Management of a Patient With Pan-Aortitis and Coronary Involvement. <i>Clinical Nuclear Medicine</i> , 2007, 32, 562-564.	0.7	9
251	<sup>99m</sup> Tc-sestamibi imaging and bone marrow karyotyping in the assessment of multiple myeloma and MGUS. <i>Nuclear Medicine Communications</i> , 2008, 29, 535-541.	0.5	9
252	Incidental detection of H <sup>1</sup> / <sub>4</sub> rtle cell adenoma by <sup>18</sup> F-choline PET/CT scan in a patient with prostate cancer. <i>Revista Espanola De Medicina Nuclear E Imagen Molecular</i> , 2013, 32, 340-341.	0.0	9

#	ARTICLE	IF	CITATIONS
253	Detectable thyroglobulin with negative imaging in differentiated thyroid cancer patients. <i>Nuklearmedizin - NuclearMedicine</i> , 2014, 53, 1-10.	0.3	9
254	Multifocal Epithelioid Hemangioendothelioma of the Lower Limbs Detected by 18F-FDG PET/MRI. <i>Clinical Nuclear Medicine</i> , 2014, 39, e402-e404.	0.7	9
255	Prognostic role of <sc>FDG</sc>â€<sc>PET</sc>/<sc>CT</sc> in differentiated thyroid carcinoma: Where are we now?. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2015, 59, 278-280.	0.9	9
256	Could short thyroid hormone withdrawal be an effective strategy for radioiodine remnant ablation in differentiated thyroid cancer patients?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 1218-1223.	3.3	9
257	Role of positron emission tomography imaging in Multiple Endocrine Neoplasia syndromes. <i>Clinical Physiology and Functional Imaging</i> , 2018, 38, 4-9.	0.5	9
258	Prognostic and predictive value of nuclear imaging in endocrine oncology. <i>Endocrine</i> , 2020, 67, 9-19.	1.1	9
259	Significance of â€œde novoâ€ appearance of thyroglobulin antibodies in patients with differentiated thyroid cancer. <i>International Journal of Biological Markers</i> , 2020, 35, 41-49.	0.7	9
260	Evidence-Based Data About Prevalence and Risk of Malignancy of Thyroid Incidentalomas Detected by Different PET Radiopharmaceuticals. <i>Current Radiopharmaceuticals</i> , 2020, 13, 89-93.	0.3	9
261	Serum chromogranin-alpha immunoradiometric assay in the diagnosis of pheochromocytoma. <i>International Journal of Biological Markers</i> , 2002, 17, 130-134.	0.7	9
262	Thyroid functional and molecular imaging. <i>Presse Medicale</i> , 2022, 51, 104116.	0.8	9
263	Immunoassay of neuron-specific enolase (NSE) and serum fragments of cytokeratin 19 (CYFRA 21.1) as tumor markers in small cell lung cancer: clinical evaluation and biological hypothesis. <i>International Journal of Biological Markers</i> , 1997, 12, 22-6.	0.7	9
264	Serum chromogranin-A assay in differential diagnosis of incidentally discovered adrenal masses. <i>Anticancer Research</i> , 2005, 25, 1547-50.	0.5	9
265	Relationship Between Left Ventricular Diastolic Function and Atrial Natriuretic Factor in Never-Treated Mild Hypertensives. <i>American Journal of Hypertension</i> , 1997, 10, 946-950.	1.0	8
266	Simultaneous Imaging of Pericardial Thymoma and Parathyroid Adenoma by Sestamibi Scan. <i>Clinical Nuclear Medicine</i> , 2008, 33, 542-544.	0.7	8
267	Evaluation of the BRAHMS KRYPTOR Thyroglobulin â€œMini-recoveryâ€ Test in Thyroid Healthy Subjects. <i>Hormone and Metabolic Research</i> , 2012, 44, 555-557.	0.7	8
268	Multiplexed immunoassay of thyroglobulin autoantibodies in patients with differentiated thyroid carcinoma. <i>Head and Neck</i> , 2012, 34, 1369-1371.	0.9	8
269	Detection rate of radiolabelled choline PET or PET/CT in hepatocellular carcinoma: an updated systematic review and meta-analysis. <i>Clinical and Translational Imaging</i> , 2019, 7, 237-253.	1.1	8
270	Diagnostic Performance of 99mTc-Methoxy-Isobuty-Isonitrile (MIBI) for Risk Stratification of Hypofunctioning Thyroid Nodules: A European Multicenter Study. <i>Diagnostics</i> , 2022, 12, 1358.	1.3	8



#	ARTICLE	IF	CITATIONS
271	Can an undetectable value of TG and a negative neck ultrasound study be considered reliable methods to assess the completeness of thyroid ablation?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2010, 37, 1039-1040.	3.3	7
272	Spurious increase in serum chromogranin A: the role of heterophilic antibodies. <i>Clinical Chemistry and Laboratory Medicine</i> , 2010, 48, 1497-1499.	1.4	7
273	Metastatic Undifferentiated Spindle Cell Sarcoma of the Thyroid Gland Evaluated by 18F-FDG PET/CT. <i>Clinical Nuclear Medicine</i> , 2015, 40, e208-e210.	0.7	7
274	Serum Markers Measured in FNA Fluids of Medullary Thyroid Carcinoma Occurring as a Cyst. <i>International Journal of Biological Markers</i> , 2016, 31, 224-227.	0.7	7
275	Histologic Outcome of Indeterminate Thyroid Nodules Classified at Low or High Risk. <i>Endocrine Pathology</i> , 2018, 29, 75-79.	5.2	7
276	Role of <sup>18</sup> F-Choline Positron Emission Tomography/Computed Tomography to Detect Structural Relapse in High-Risk Differentiated Thyroid Cancer Patients. <i>Thyroid</i> , 2019, 29, 549-556.	2.4	7
277	Variations in radioiodine ablation: decision-making after total thyroidectomy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 554-560.	3.3	7
278	“Quid autem vides festucam in oculo fratris tui et trabem in oculo tuo non vides” on the hyperthyroidism-induced mortality and antithyroid drug-induced side effects in the era of radioiodine fake news. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 1342-1344.	3.3	7
279	Circulating pro-gastrin releasing peptide (ProGRP) in patients with medullary thyroid carcinoma. <i>Clinical Chemistry and Laboratory Medicine</i> , 2021, 59, 1569-1573.	1.4	7
280	Advanced differentiated thyroid cancer: when to stop radioiodine?. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 63, 267-270.	0.4	7
281	Integration of Baseline Metabolic Parameters and Mutational Profiles Predicts Long-Term Response to First-Line Therapy in DLBCL Patients: A Post Hoc Analysis of the SAKK38/07 Study. <i>Cancers</i> , 2022, 14, 1018.	1.7	7
282	To give or not to give? A critical appraisal of a clinical trial on radioiodine treatment. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, , .	3.3	7
283	Steroid responsive encephalopathy associated with autoimmune thyroiditis (SREAT) with negative thyroperoxidase antibodies. <i>European Journal of Clinical Investigation</i> , 2008, 38, 693-694.	1.7	6
284	Elevated calcitonin and procalcitonin levels in nonmedullary benign and malignant thyroid nodules. <i>Clinical Endocrinology</i> , 2010, 72, 852-853.	1.2	6
285	Radioguided Surgery of Thyroid Carcinoma Recurrences. <i>Clinical Nuclear Medicine</i> , 2013, 38, e207-e209.	0.7	6
286	When to perform positron emission tomography/computed tomography or radionuclide bone scan in patients with recently diagnosed prostate cancer. <i>Cancer Management and Research</i> , 2013, 5, 123.	0.9	6
287	BRAF (V600E) mutation in isthmic malignant thyroid nodules. <i>Clinical Endocrinology</i> , 2016, 84, 152-153.	1.2	6
288	A “new/old method” for TSH stimulation: could a third way to prepare DTC patients for 131I remnant ablation possibly exist?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 221-223.	3.3	6

#	ARTICLE	IF	CITATIONS
289	Measuring thyroglobulin in patients with thyroglobulin autoantibodies: evaluation of the clinical impact of BRAHMS Kryptor <sup>®</sup> Tg-minirecovery test in a large series of patients with differentiated thyroid carcinoma. <i>Clinical Chemistry and Laboratory Medicine</i> , 2019, 57, 1185-1191.	1.4	6
290	<sup>99m</sup> Tc-Perchnetate Scintigraphy Predicts Successful Postoperative Ablation in Differentiated Thyroid Carcinoma Patients Treated with Low Radioiodine Activities. <i>Endocrinology and Metabolism</i> , 2019, 34, 63.	1.3	6
291	Dedicated neck 18 F-FDG PET/CT: An additional tool for risk assessment in thyroid nodules at ultrasound intermediate risk. <i>Clinical Endocrinology</i> , 2019, 90, 737-743.	1.2	6
292	New! F-18-based PET/CT for sodium-iodine-symporter-targeted imaging!. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 2484-2486.	3.3	6
293	Radioiodine therapy of Graves' disease. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 65, 132-137.	0.4	6
294	Thyroid dysfunctions induced by molecular cancer therapies: a synopsis for nuclear medicine thyroidologists. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 3355-3360.	3.3	6
295	Copper, PET/CT and prostate cancer: a systematic review of the literature. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 64, 382-392.	0.4	6
296	Immunoradiometric assay of chromogranin A in the diagnosis of small cell lung cancer: comparative evaluation with neuron-specific enolase. <i>International Journal of Biological Markers</i> , 2001, 16, 50-5.	0.7	6
297	The role of thyroglobulin doubling time in differentiated thyroid cancer: a meta-analysis. <i>Endocrine Connections</i> , 2022, 11, .	0.8	6
298	Redefining functional sensitivity of thyroglobulin assay on Immulite platform: implications in thyroid cancer management. <i>Clinical Chemistry and Laboratory Medicine</i> , 2007, 45, 1523-4.	1.4	5
299	Images in Endocrine Pathology: a Starry-Sky in the Thyroid. <i>Endocrine Pathology</i> , 2012, 23, 79-81.	5.2	5
300	Left atrial metastasis of H <sup>125</sup> I-thyroid carcinoma mimicking myxoma. <i>Journal of Nuclear Cardiology</i> , 2014, 21, 406-407.	1.4	5
301	An Unusual Case of Plasmablastic Lymphoma Presenting as Paravertebral Mass Evaluated by 18F-FDG PET/CT. <i>Nuclear Medicine and Molecular Imaging</i> , 2014, 48, 89-90.	0.6	5
302	Small cell carcinoma of the thyroid gland with a solid brain metastasis detected by F-18-FDG PET/CT. <i>Endocrine</i> , 2014, 46, 682-683.	1.1	5
303	Letter to the Editor: What Is the Role of Serum Thyroglobulin Measurement in Patients With Differentiated Thyroid Cancer Treated Without Radioactive Iodine?. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 2113-2114.	1.8	5
304	METABOLIC HETEROGENEITY OF BASELINE 18-FDG PET-CT SCAN PREDICTS OUTCOME IN PRIMARY MEDIASTINAL B-CELL LYMPHOMA.. <i>Hematological Oncology</i> , 2017, 35, 60-61.	0.8	5
305	Only a Rapid Complete Biochemical Remission After 131I-Therapy is Associated with an Unimpaired Life Expectancy in Differentiated Thyroid Cancer. <i>Hormone and Metabolic Research</i> , 2017, 49, 860-868.	0.7	5
306	Use of anti-thyroid drugs in patients with hyperthyroidism: a case for shared decision-making. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 2408-2409.	3.3	5

#	ARTICLE	IF	CITATIONS
307	An unsuspecting thyroid nodule with fatal outcome. <i>Hormones</i> , 2019, 18, 321-324.	0.9	5
308	Variations in Radioiodine Therapy in Europe – Decision-Making after Total Thyroidectomy. <i>Oncology</i> , 2021, , .	0.9	5
309	An essential practice summary of the new EANM guidelines for parathyroid imaging. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 66, .	0.4	5
310	Functional and molecular thyroid imaging. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 66, .	0.4	5
311	Thyroid Remnant Estimation by Tc-99m-Sestamibi Scanning Predicts the Effectiveness of rhTSH-Stimulated I-131 Ablation in Patients With Differentiated Thyroid Carcinoma. <i>Clinical Nuclear Medicine</i> , 2011, 36, 781-785.	0.7	4
312	Evaluation of serum parathyroid hormone-related peptide in hyperthyroid patients. <i>European Journal of Clinical Investigation</i> , 2011, 41, 93-97.	1.7	4
313	Letter to the editor: Thyroglobulin-guided 131I ablation in low-risk differentiated thyroid carcinoma: Is the yardstick accurate enough?. <i>Head and Neck</i> , 2011, 33, 1379-1380.	0.9	4
314	Ruling Out <sup>131</sup> I Ablation in Low-Risk Differentiated Thyroid Carcinoma Basing on Thyroglobulin Measurement. <i>Thyroid</i> , 2011, 21, 809-810.	2.4	4
315	Thyroglobulin and Thyroglobulin Autoantibodies Measurement Using the Automated KRYPTOR® Platform in Patients with Differentiated Thyroid Carcinoma. <i>Hormone and Metabolic Research</i> , 2011, 43, 728-730.	0.7	4
316	Unusual Muscular Metastases From Papillary Thyroid Carcinoma Detected by Fluorine-18-Fluorodeoxyglucose PET/MRI. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 2208-2209.	1.8	4
317	Bone Marrow Involvement in Unknown Acute Myeloid Leukemia Detected by 18F-FDG PET/MRI. <i>Clinical Nuclear Medicine</i> , 2015, 40, e486-e487.	0.7	4
318	Euthyroid Graves™ disease with spurious hyperthyroidism: a diagnostic challenge. <i>Clinical Chemistry and Laboratory Medicine</i> , 2019, 57, e94-e96.	1.4	4
319	18F-Fluoride (18F-NaF) PET/CT in medullary thyroid carcinoma: far from evidence, far from guidelines!. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 527-528.	3.3	4
320	Is isthmic enucleo-resection a reliable treatment for isthmic differentiated thyroid carcinoma? A note of caution. <i>Journal of Endocrinological Investigation</i> , 2020, 43, 1829-1830.	1.8	4
321	The Role of 2-[18F]-FDG PET/CT in Detecting Richter Transformation in Chronic Lymphocytic Leukemia: A Systematic Review. <i>Radiation</i> , 2021, 1, 65-76.	0.6	4
322	Usefulness of 123I-spect/ct to assess the response to initial therapy in differentiated thyroid cancer patients. <i>Endocrine</i> , 2021, 74, 193-196.	1.1	4
323	Tissue polypeptide-specific antigen (TPS) immunoassay in the diagnosis and clinical staging of prostatic carcinoma. Comparison with prostate-specific antigen (PSA). <i>International Journal of Biological Markers</i> , 1997, 12, 27-34.	0.7	4
324	CT evaluation of lung infiltrates in the two months preceding the Coronavirus disease 19 pandemic in Canton Ticino (Switzerland): were there suspicious cases before the official first case?. <i>Radiologia Medica</i> , 2022, 127, 360-368.	4.7	4

#	ARTICLE	IF	CITATIONS
325	False-positive calcitonin results in patients with benign goiter. <i>Clinical Chemistry and Laboratory Medicine</i> , 2012, 50, 407-8.	1.4	3
326	Letter to the Editor: Lymph nodes thyroglobulin measurement after rhTSH stimulation. <i>Head and Neck</i> , 2013, 35, 146-146.	0.9	3
327	Splenosis Mimicking Relapse of a Neuroendocrine Tumor at Gallium-68-DOTATOC PET/CT. <i>Nuclear Medicine and Molecular Imaging</i> , 2014, 48, 163-165.	0.6	3
328	An Unusual Case of Extraskeletal Retroperitoneal Osteosarcoma Incidentally Detected by 18F-FDG PET/CT. <i>Nuclear Medicine and Molecular Imaging</i> , 2014, 48, 249-250.	0.6	3
329	Squamous Cell Carcinoma of the Tonsil Incidentally Detected by 18F-Choline PET/CT. <i>Clinical Nuclear Medicine</i> , 2015, 40, 93-95.	0.7	3
330	Clinical role and accuracy of 18F-FDG PET in evaluating disease activity in patients with chronic inflammatory bowel disease: an updated systematic review and a bivariate meta-analysis. <i>Clinical and Translational Imaging</i> , 2017, 5, 303-313.	1.1	3
331	Prevalence and clinical significance of incidental 18F-FDG uptake in the pituitary. <i>Clinical and Translational Imaging</i> , 2020, 8, 237-242.	1.1	3
332	Medical treatment of thyrotoxicosis. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 65, 113-123.	0.4	3
333	A multicenter survey of current practices of 99mTc-methoxy-isobutyl-isonitrile (MIBI) imaging for the diagnosis of thyroid nodules: more standardization is essential. <i>Clinical and Translational Imaging</i> , 2021, 9, 413-422.	1.1	3
334	Evaluation of the serum markers CEA, NSE, TPS and CYFRA 21.1 in lung cancer. <i>International Journal of Biological Markers</i> , 1995, 10, 156-60.	0.7	3
335	How to approach clinically discordant FT4 results when changing testing platforms: real-world evidence. <i>Endocrine</i> , 2022, 77, 333-339.	1.1	3
336	Diagnostic criteria for detection of postinfarction ischemia by quantitative analysis of stepwise dobutamine radionuclide ventriculography. <i>Journal of Nuclear Cardiology</i> , 1999, 6, 514-521.	1.4	2
337	A hypothyroid patient with increased free thyroid hormones. <i>Clinical Chemistry and Laboratory Medicine</i> , 2008, 46, 1650-1.	1.4	2
338	Toxoplasmic Lymphadenitis Mimicking a Metastatic Thyroid Carcinoma at 18F-FDG-PET/CT. <i>Nuclear Medicine and Molecular Imaging</i> , 2013, 47, 289-290.	0.6	2
339	A Rare Case of Mucinous Cystadenoma of the Lung Mimicking Malignancy at 18F-FDG PET/CT. <i>Clinical Nuclear Medicine</i> , 2014, 39, e331-e333.	0.7	2
340	A Rare Case of Synchronous Fetal Type Adenocarcinoma and Mucinous Adenocarcinoma of the Lung Evaluated by 18F-FDG PET/CT. <i>Clinical Nuclear Medicine</i> , 2014, 39, e384-e386.	0.7	2
341	Discordance rate between radiolabelled choline PET/CT and bone scintigraphy in detecting bone metastases in patients with prostate cancer: a meta-analysis. <i>Clinical and Translational Imaging</i> , 2015, 3, 133-140.	1.1	2
342	H <sup>125</sup> I-thyroglobulin Cells Adenoma of the Thyroid with Post-surgical Implants in the Neck: Clinical, Morphological, and Molecular Analysis of Three Cases. <i>Endocrine Pathology</i> , 2016, 27, 338-345.	5.2	2

#	ARTICLE	IF	CITATIONS
343	One-stop-shop radioiodine dosimetry in patients with Gravesâ€™ disease. <i>Endocrine</i> , 2017, 56, 220-221.	1.1	2
344	Letter to the Editor: â€œPostoperative Thyroglobulin and Neck Ultrasound in the Risk Restratification and Decision to Perform 131I Ablationâ€• <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 1783-1784.	1.8	2
345	The Significance of Having an Excellent Patient's Comfort with Thyroid Core Needle Biopsy. <i>Endocrinology and Metabolism</i> , 2018, 33, 53.	1.3	2
346	Prognosis of patients with differentiated thyroid carcinomas having a preoperative cytological report of indeterminate at low or high risk. A multicenter study. <i>Endocrine</i> , 2019, 66, 557-562.	1.1	2
347	The impact of biotin interference on laboratory testing and patient diagnosis in clinical practice. <i>International Journal of Pharmacokinetics</i> , 2019, 4, IPK01.	0.5	2
348	18F-FDG-PET/CT Imaging in Advanced Glottic Cancer: A Tool for Clinical Decision in Comparison with Conventional Imaging. <i>Contrast Media and Molecular Imaging</i> , 2019, 2019, 1-12.	0.4	2
349	Thyroid Imaging. , 2019, , 545-564.		2
350	Multimodal therapy of advanced differentiated thyroid cancer, with emphasis on the role of radioiodine. <i>Clinical and Translational Imaging</i> , 2019, 7, 427-435.	1.1	2
351	The role of systematic review and metaâ€™analysis in modern cytopathology. <i>Cancer Cytopathology</i> , 2020, 128, 89-91.	1.4	2
352	The new Roche Elecsys TSH assay conforms with current IFCC C-STFT standards. <i>Clinical Chemistry and Laboratory Medicine</i> , 2021, 59, e445-e448.	1.4	2
353	Role of Positron Emission Tomography (PET/CT) in Primary Mediastinal Large B Cell Lymphoma (PMLBCL): Preliminary Results of an International Phase II Trial (IELSG-26 Study) Conducted On Behalf of the International Extranodal Lymphoma Study Group (IELSG), the Fondazione Italiana Linfomi (FIL) and the UK NCRI Lymphoma Group. <i>Blood</i> . 2012, 120, 1566-1566.	0.6	2
354	Diagnostic value of serum chromogranin-A combined with MIBG scintigraphy in patients with adrenal incidentalomas. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2008, 52, 84-88.	0.4	2
355	Thyroglobulin measurement in differentiated thyroid carcinoma management. <i>Expert Review of Endocrinology and Metabolism</i> , 2008, 3, 117-125.	1.2	1
356	A Papillary Thyroid Tumor Detected by 18F-FDG-PET/CT in a Pediatric Patient with Cowden Syndrome. <i>Nuclear Medicine and Molecular Imaging</i> , 2013, 47, 143-145.	0.6	1
357	Iodine-131 administration and risk of cancer: â€œAppearances can be deceptiveâ€• <i>Hormones</i> , 2013, 12, 312-314.	0.9	1
358	Current Role and Future Perspectives of Radioiodinated MIBG in the Evaluation of Dementia with Lewy Bodies. <i>Current Radiopharmaceuticals</i> , 2014, 7, 75-78.	0.3	1
359	Solitary Plasmacytoma of the Sternum Mimicking Bone Metastasis in a Patient with a History of Breast Cancer Evaluated by F-18-FDG PET/CT. <i>Nuclear Medicine and Molecular Imaging</i> , 2014, 48, 169-170.	0.6	1
360	An Unusual Case of Extramedullary Plasmacytoma of the Hypopharynx Detected by 18F-FDG PET/CT. <i>Nuclear Medicine and Molecular Imaging</i> , 2014, 48, 328-329.	0.6	1

#	ARTICLE	IF	CITATIONS
361	Hypercalcitoninemia and thyroid nodules. <i>Diagnostic Cytopathology</i> , 2014, 42, 970-973.	0.5	1
362	An Unusual Case of Diffuse Large B-Cell Lymphoma Involving the Vulva Evaluated by 18F-FDG PET/CT. <i>Clinical Nuclear Medicine</i> , 2014, 39, e439-e441.	0.7	1
363	Colorectal Carcinoma With Bone Metastases Detected by 18F-Choline PET/CT. <i>Clinical Nuclear Medicine</i> , 2014, 39, e246-e248.	0.7	1
364	A Rare Case of Metastatic Clear Cell Carcinoma of the Müllerian System Originating From the Peritoneum Assessed by 18F-FDG PET/CT. <i>Clinical Nuclear Medicine</i> , 2015, 40, e58-e60.	0.7	1
365	Images in Endocrine Pathology: Similar, But Not the Same!. <i>Endocrine Pathology</i> , 2015, 26, 187-189.	5.2	1
366	A rare case of idiopathic granulomatous hepatitis presenting as tumoral lesion detected by 18F-FDG-PET/CT. <i>Annals of Hepatology</i> , 2016, 15, 121-122.	0.6	1
367	Early diagnosis by FNA cytology should not influence the outcome of differentiated thyroid cancer. <i>Endocrine Journal</i> , 2016, 63, 367-373.	0.7	1
368	Malignant Mucous Cells in a Thyroid Aspirate: Looking for a Source. <i>Endocrine Pathology</i> , 2016, 27, 79-82.	5.2	1
369	Circulating Mucins and Cytokeratins in Aggressive Thyroid Cancers. , 2018, , 175-189.		1
370	Re: "Diagnostic Performance of Technetium-99m Methoxy-Isobutyl-Isonitrile for Differentiation of Malignant Thyroid Nodules: A Systematic Review and Meta-Analysis" by Kim et al. ( <i>Thyroid</i> ) <i>Tj ETQq</i> 0.0 0 rgBT1/Overlock		
371	Free-thyroxine standardization: waiting for Godot while well serving our patients today. <i>Clinical Chemistry and Laboratory Medicine</i> , 2021, 59, e225-e226.	1.4	1
372	An ectopic, dysmorphic and atypical parathyroid adenoma. <i>Endocrine</i> , 2021, 74, 200-201.	1.1	1
373	Limited Benefit of Additional Contrast-Enhanced CT to End-of- Treatment PET-CT Evaluation in Patients with Follicular Lymphoma. <i>Blood</i> , 2016, 128, 5925-5925.	0.6	1
374	Radioiodine dosimetry in advanced thyroid cancer. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 63, 227-228.	0.4	1
375	Asinus in Tegulis"basing stark warning messages on insufficient methodology. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, , 1.	3.3	1
376	Usefulness of 18F-FDG PET/CT in syphilitic aortitis. <i>Clinical Rheumatology</i> , 2013, 32, 1247-1247.	1.0	0
377	Cromogranina A e peptidi derivati: fisiopatologia e importanza clinica. <i>L Endocrinologo</i> , 2015, 16, 116-122.	0.0	0
378	Mycosis Fungoides Involving the Lungs Detected by 18F-FDG PET/CT. <i>Archivos De Bronconeumologia</i> , 2015, 51, 521-522.	0.4	0

#	ARTICLE	IF	CITATIONS
379	(99m)Tc-MIBI Uptake in a Thyroid Adenoma with Diffuse Adipose Metaplasia. Nuclear Medicine and Molecular Imaging, 2016, 50, 362-364.	0.6	0
380	Radionuclide Imaging of Medullary Thyroid Carcinoma. , 2017, , 381-399.		0
381	Re: Low-Dose Radioactive Iodine Ablation Is Sufficient in Patients With Small Papillary Thyroid Cancer Having Minor Extrathyroidal Extension and Central Lymph Node Metastasis (T3 N1a). Clinical Nuclear Medicine, 2018, 43, 631-632.	0.7	0
382	Unusual case of tumor of unknown origin found by 18 F-FDG PET/CT: Metastatic clear cell carcinoma of the thyroid gland. Revista Espanola De Medicina Nuclear E Imagen Molecular, 2018, 37, 54-56.	0.1	0
383	Procalcitonin: Are We Ready for Clinical Use?. , 2018, , 151-157.		0
384	Measurement of Thyroid Tumor Markers on Fine-Needle Washouts. , 2018, , 193-200.		0
385	Thyroglobulin and Thyroglobulin Antibodies. , 2018, , 65-91.		0
386	Caso inusual de tumor de origen desconocido detectado con 18 F-FDG PET/TC: carcinoma de células claras de la glándula tiroides metastásico. Revista Espanola De Medicina Nuclear E Imagen Molecular, 2018, 37, 54-56.	0.0	0
387	Clinical diagnosis of endocrine diseases. Minerva Endocrinology, 2018, 43, 259-260.	0.6	0
388	Thyroid cancer recurrence in the HiLo trial. Lancet Diabetes and Endocrinology,the, 2019, 7, 252.	5.5	0
389	Thyroglobulin and Tg Antibodies. , 2019, , 655-671.		0
390	Thermal ablation meta-analysis: the need of careful appraisal of meta-analysis methodology. Endocrine, 2020, 67, 270-271.	1.1	0
391	Laboratory Investigation of the 900-km Lapland Extreme Challenge. Annals of Laboratory Medicine, 2020, 40, 92-94.	1.2	0
392	Update on diagnosis and treatment of hyperthyroidism. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2021, 65, 89-90.	0.4	0
393	A spotlight on redifferentiation strategies and target modulation in differentiated thyroid cancer. Clinical and Translational Imaging, 2021, 9, 405-408.	1.1	0
394	Two Birds with One Stone: Skull Base Meningioma and Jugulotympanic Paragangliomas with Somatostatin Receptor Positron Emission Tomography. Diagnostics, 2021, 11, 1669.	1.3	0
395	Comment on: Report of One Case of Malignancy Among 17 Autonomous Thyroid Nodules in Children and Adolescents. Journal of Paediatrics and Child Health, 2021, , .	0.4	0
396	Late Blood Pool Images After Tc-99m Tetrofosmin Injection in a Patient With Monoclonal Gammopathy of Uncertain Significance and Immunologic Disorders. Clinical Nuclear Medicine, 2000, 25, 536-538.	0.7	0

#	ARTICLE	IF	CITATIONS
397	Radioiodine Therapy: Current Imaging Concepts Introduction. , 2012, , 224-230.		0
398	Medullary Thyroid Carcinoma. , 2016, , 83-88.		0
399	Thyroid Autonomy. , 2016, , 47-51.		0
400	Nuclear Medicine Techniques. , 2016, , 13-19.		0
401	Gravesâ€™ Disease. , 2016, , 41-45.		0
402	Differentiated Thyroid Carcinoma. , 2016, , 73-82.		0
403	Correlation between PSA kinetics and detection rate of PSMA-PET in the setting of biochemical recurrent prostate cancer: A systematic review and meta-analysis.. Journal of Clinical Oncology, 2019, 37, 71-71.	0.8	0
404	<sup>18</sup> F-FET. , 2020, , 83-88.		0
405	Introduction to Different PET Radiopharmaceuticals and Hybrid Modalities (PET/CT and PET/MRI). , 2020, , 3-15.		0
406	Swiss Congress of Nuclear Medicine 2010. Nuklearmedizin - NuclearMedicine, 2010, 49, N15.	0.3	0
407	Nuclear medicine therapy of thyroid cancer post-thyroidectomy. , 2022, , .		0
408	Unusual [ <sup>18</sup> F]-fluorocholine uptake in a hot thyroid nodule and ipsilateral parathyroid adenoma. Endocrine, 2022, , 1.	1.1	0
409	Malignant thyroid nodule topography as additional risk factor for lymph-node metastases in differentiated thyroid cancer patients. European Archives of Oto-Rhino-Laryngology, 2022, , 1.	0.8	0